Controversies in Surveillance and Early Diagnosis of Hepatocellular Carcinoma

被引:16
作者
Kim, Do Young [1 ,2 ,3 ]
Kim, Jin Wook [4 ]
Kuromatsu, Ryoko [5 ]
Ahn, Sang Hoon [1 ,2 ,3 ]
Torimura, Takuji [5 ]
Sherman, Morris [6 ,7 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Yonsei Liver Canc Early Diag Clin, Coll Med, Seoul, South Korea
[3] Seoul Natl Univ, Liver Cirrhosis Clin Res Ctr, Coll Med, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea
[5] Kurume Univ, Sch Med, Dept Med, Fukuoka, Japan
[6] Univ Toronto, Dept Med, Toronto, ON, Canada
[7] Univ Hlth Network, Toronto, ON, Canada
关键词
Hepatocellular carcinoma; Surveillance; Biomarker; HEPATITIS-B-VIRUS; GAMMA-CARBOXY PROTHROMBIN; SERUM ALPHA-FETOPROTEIN; CHRONIC LIVER-DISEASE; CIRRHOTIC-PATIENTS; SEMIANNUAL SURVEILLANCE; SURVIVAL; TRANSPLANTATION; ULTRASONOGRAPHY; MANAGEMENT;
D O I
10.1159/000333261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The surveillance of hepatocellular carcinoma (HCC) is an established approach to detect early cancers in patients with defined risks. However, there are still varied controversies and issues to be addressed regarding the optimal surveillance methods and interval. Moreover, there are discrepancies in the opinion or practice of HCC surveillance between Eastern and Western countries. The Western strategy of ultrasound without a biomarker such as alpha-fetoprotein reflects the cost-effective utilization of limited resources. On the contrary, combined measurements of biomarkers in Eastern countries are based on the assumption that increased detection of early cancers could result in an overall survival benefit. To address this complicated issue, a prospective study comparing different surveillance tests might be required. More importantly, discovery of a novel biomarker with higher performance would be an alternative. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:56 / 60
页数:5
相关论文
共 33 条
[1]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[2]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[5]   Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States [J].
Carr, Brian I. ;
Kanke, Futoshi ;
Wise, Margaret ;
Satomura, Shinji .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (03) :776-782
[6]  
Cedrone A, 2000, HEPATO-GASTROENTEROL, V47, P1654
[7]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[8]   Screening for hepatocellular carcinoma [J].
Collier, J ;
Sherman, M .
HEPATOLOGY, 1998, 27 (01) :273-278
[9]   α-fetoprotein and ultrasonography screening for hepatocellular carcinoma [J].
Daniele, B ;
Bencivenga, A ;
Megna, AS ;
Tinessa, V .
GASTROENTEROLOGY, 2004, 127 (05) :S108-S112
[10]  
DIBISCEGLIE AM, 1989, CANCER, V64, P2117, DOI 10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO